Evidence map›Paper›PMID 26087254›Full record

ArticlePloS one2015

Significant Reductions in Mortality in Hospitalized Patients with Systemic Lupus Erythematosus in Washington State from 2003 to 2011.

Louisa B Goss, Justin R Ortiz, Daryl M Okamura, Kristen Hayward, Christopher H Goss

Erratum issuedAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Louisa B GossDepartment of Medicine, University of Washington, Seattle, Washington, United States of America.
Justin R OrtizDepartment of Medicine, University of Washington, Seattle, Washington, United States of America; Department of Global Health, University of Washington, Seattle, Washington, United States of America.
Daryl M OkamuraDepartment of Pediatrics, Division of Nephrology, University of Washington, Seattle, Washington, United States of America; Seattle Children's Research Institute, Seattle,Washington, United States of America.
Kristen HaywardSeattle Children's Research Institute, Seattle,Washington, United States of America; Department of Pediatrics, Division of Rheumatology, University of Washington, Seattle, Washington, United States of America.
Christopher H GossDepartment of Medicine, University of Washington, Seattle, Washington, United States of America; Department of Pediatrics, Division of Rheumatology, University of Washington, Seattle, Washington, United States of America; Department of Pediatrics, Division of Pulmonary, University of Washington, Seattle, Washington, United States of America.

Funding

Translational Research Center to Expedite Novel Therapies in Cystic FibrosisP30DK089507 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI Christopher Hooper Goss, Lucas R Hoffman · 2010 to 2026
$21.4M
Proof of Principle Evaluation of IV Gallium Nitrate in Patients with CFUM1HL119073 · NHLBI · UNIVERSITY OF WASHINGTON · PI GOSS, CHRISTOPHER HOOPER, SINGH, PRADEEP K · 2013 to 2017
$4.8M
Early Intervention in Pulmonary Exacerbation in CFR01HL103965 · NHLBI · UNIVERSITY OF WASHINGTON · PI GOSS, CHRISTOPHER HOOPER, LECHTZIN, NOAH · 2010 to 2014
$3.8M
Investigating treatment resistance mechanisms in chronic bacterial infectionsR01AI101307 · NIAID · UNIVERSITY OF WASHINGTON · PI BRUCE, JAMES EDWARD, MANOIL, COLIN · 2012 to 2016
$2.9M
Regulation of host inflammatory responses and outcome in melioidosis by TLR5R01HL113382 · NHLBI · UNIVERSITY OF WASHINGTON · PI WEST, TIMOTHY EOIN · 2012 to 2016
$2.6M
Phase 2 Study of Intravenous Gallium Nitrate in the Treatment of Cystic FibrosisR01FD003704 · FDA · UNIVERSITY OF WASHINGTON · PI GOSS, CHRISTOPHER HOOPER · 2009 to 2018
$2.0M
FDA HHS R01 FD003704FDA HHS R01FD003704NHLBI NIH HHS R01 HL103965NHLBI NIH HHS R01HL103965NHLBI NIH HHS R01 HL113382NHLBI NIH HHS R01HL113382NHLBI NIH HHS U M1HL119073NIAID NIH HHS R01 AI101307NIAID NIH HHS R01AI101307NIDDK NIH HHS P30 DK089507NIDDK NIH HHS P30DK089507
6 · The paper itself

Abstract

backgroundSystemic lupus erythematosus (SLE or lupus) is an autoimmune multisystem disease. While a complete understanding of lupus' origins, mechanisms, and progression is not yet available, a number of studies have demonstrated correlations between disease prevalence and severity, gender, and race. There have been few population based studies in the United States.

objectivesTo assess temporal changes in demographics and hospital mortality of patients with lupus in Washington State from 2003 to 2011. STUDY

designThis study used data from the Healthcare Cost and Utilization Project (HCUP), a patient information database, and data from the Washington State census to study a group of patients in the state. Lupus hospitalizations were defined as any hospitalization with an ICD-9-CM diagnosis code for systemic lupus erythematosus. Regression analysis was used to assess the effect of calendar time on demographics and hospital outcomes.

resultsThere were a total of 18,905 patients in this study with a diagnostic code for lupus. The mean age of the group was 51.5 years (95% CI: 50.6-52.3) in 2003 and 51.3 years (95% CI: 50.6-52.0) in 2011. The population was 88.6% female. Blacks were 2.8 times more likely to have a lupus hospitalization than whites when compared to the Washington population. While hospital mortality decreased during this eight year period (3.12% in 2003 to 1.28% in 2011, p=0.001) hospital length of stay remained statistically unchanged at an average of 4.9 days during that eight year period. We found a significant decrease in annual hospital mortality over the study period [odds ratio(OR): 0.92 per year, 95% CI 0.88-0.96, P<0.001]. Hospital mortality was higher in males (2.6% male death to 1.8% female death).

conclusionsIn this large group of hospitalized lupus patients in Washington, hospital length of stay remained relatively stable over time but hospital mortality decreased by over 50% over the eight year study period.

Indexed as

AdolescentAdultAgedDatabases, FactualFemaleHospitalizationHospital MortalityHumansLength of StayLupus Erythematosus, SystemicMaleMiddle AgedPrevalenceWashingtonYoung Adult

Identifiers

PMID26087254
PMCPMC4473009

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.